| Date | Time | Source | Headline | Symbol | Company |
| 05/30/2024 | 5:55PM | GlobeNewswire Inc. | QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/23/2024 | 6:00PM | GlobeNewswire Inc. | Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/16/2024 | 4:05PM | GlobeNewswire Inc. | New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/15/2024 | 5:49PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/15/2024 | 5:48PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/15/2024 | 4:24PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/14/2024 | 4:26PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/13/2024 | 4:24PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/13/2024 | 12:14PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/08/2024 | 8:23AM | IH Market News | Reddit Rises 15% After First Quarterly Report, Upstart and Twilio Plunge Due to Weak Q2 Forecast, and More in Earnings | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/08/2024 | 8:14AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/07/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/07/2024 | 4:05PM | GlobeNewswire Inc. | Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA | NASDAQ:MYGN | Myriad Genetics Inc |
| 05/07/2024 | 9:00AM | GlobeNewswire Inc. | Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business | NASDAQ:MYGN | Myriad Genetics Inc |
| 04/30/2024 | 4:05PM | GlobeNewswire Inc. | Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 | NASDAQ:MYGN | Myriad Genetics Inc |
| 04/17/2024 | 8:00AM | GlobeNewswire Inc. | Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor | NASDAQ:MYGN | Myriad Genetics Inc |
| 04/16/2024 | 9:15AM | GlobeNewswire Inc. | New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen | NASDAQ:MYGN | Myriad Genetics Inc |
| 04/09/2024 | 8:00AM | GlobeNewswire Inc. | Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing | NASDAQ:MYGN | Myriad Genetics Inc |
| 03/21/2024 | 9:40PM | GlobeNewswire Inc. | Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date | NASDAQ:MYGN | Myriad Genetics Inc |
| 03/20/2024 | 4:05PM | GlobeNewswire Inc. | Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device | NASDAQ:MYGN | Myriad Genetics Inc |
| 03/04/2024 | 4:18PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/28/2024 | 8:31AM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/27/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/27/2024 | 4:05PM | GlobeNewswire Inc. | Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fo | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/27/2024 | 9:15AM | GlobeNewswire Inc. | Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3 | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/26/2024 | 4:12PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/26/2024 | 4:09PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/21/2024 | 4:05PM | GlobeNewswire Inc. | Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/15/2024 | 4:05PM | GlobeNewswire Inc. | Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health | NASDAQ:MYGN | Myriad Genetics Inc |
| 02/14/2024 | 4:47PM | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:MYGN | Myriad Genetics Inc |